These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 32075969)

  • 21. Structural review of PPARγ in complex with ligands: Cartesian- and dihedral angle principal component analyses of X-ray crystallographic data.
    Kaupang Å; Laitinen T; Poso A; Hansen TV
    Proteins; 2017 Sep; 85(9):1684-1698. PubMed ID: 28543443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PPARγ helix 12 exhibits an antagonist conformation.
    Fratev F
    Phys Chem Chem Phys; 2016 Apr; 18(13):9272-80. PubMed ID: 26975214
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ligand and receptor dynamics contribute to the mechanism of graded PPARγ agonism.
    Hughes TS; Chalmers MJ; Novick S; Kuruvilla DS; Chang MR; Kamenecka TM; Rance M; Johnson BA; Burris TP; Griffin PR; Kojetin DJ
    Structure; 2012 Jan; 20(1):139-50. PubMed ID: 22244763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ligand-Dependent Corepressor (LCoR) Is a Rexinoid-Inhibited Peroxisome Proliferator-Activated Receptor γ-Retinoid X Receptor α Coactivator.
    Shalom-Barak T; Liersemann J; Memari B; Flechner L; Devor CE; Bernardo TM; Kim S; Matsumoto N; Friedman SL; Evans RM; White JH; Barak Y
    Mol Cell Biol; 2018 May; 38(9):. PubMed ID: 29463649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping.
    Sheu SH; Kaya T; Waxman DJ; Vajda S
    Biochemistry; 2005 Feb; 44(4):1193-209. PubMed ID: 15667213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities.
    Lu IL; Huang CF; Peng YH; Lin YT; Hsieh HP; Chen CT; Lien TW; Lee HJ; Mahindroo N; Prakash E; Yueh A; Chen HY; Goparaju CM; Chen X; Liao CC; Chao YS; Hsu JT; Wu SY
    J Med Chem; 2006 May; 49(9):2703-12. PubMed ID: 16640330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modification of the Orthosteric PPARγ Covalent Antagonist Scaffold Yields an Improved Dual-Site Allosteric Inhibitor.
    Brust R; Lin H; Fuhrmann J; Asteian A; Kamenecka TM; Kojetin DJ
    ACS Chem Biol; 2017 Apr; 12(4):969-978. PubMed ID: 28165718
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Different binding and recognition modes of GL479, a dual agonist of Peroxisome Proliferator-Activated Receptor α/γ.
    dos Santos JC; Bernardes A; Giampietro L; Ammazzalorso A; De Filippis B; Amoroso R; Polikarpov I
    J Struct Biol; 2015 Sep; 191(3):332-40. PubMed ID: 26185032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rational discovery of a novel interface for a coactivator in the peroxisome proliferator-activated receptor gamma: theoretical implications of impairment in type 2 diabetes mellitus.
    Shiraki T; Kodama TS; Jingami H; Kamiya N
    Proteins; 2005 Feb; 58(2):418-25. PubMed ID: 15558556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peroxisome proliferator-activated receptor gamma (PPARγ) has multiple binding points that accommodate ligands in various conformations: Structurally similar PPARγ partial agonists bind to PPARγ LBD in different conformations.
    Ohashi M; Gamo K; Oyama T; Miyachi H
    Bioorg Med Chem Lett; 2015 Jul; 25(14):2758-62. PubMed ID: 26025876
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro.
    Burgermeister E; Schnoebelen A; Flament A; Benz J; Stihle M; Gsell B; Rufer A; Ruf A; Kuhn B; Märki HP; Mizrahi J; Sebokova E; Niesor E; Meyer M
    Mol Endocrinol; 2006 Apr; 20(4):809-30. PubMed ID: 16373399
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural Basis for the Enhanced Anti-Diabetic Efficacy of Lobeglitazone on PPARγ.
    Jang JY; Bae H; Lee YJ; Choi YI; Kim HJ; Park SB; Suh SW; Kim SW; Han BW
    Sci Rep; 2018 Jan; 8(1):31. PubMed ID: 29311579
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ligand-induced stabilization and activation of peroxisome proliferator-activated receptor gamma.
    Gani OA; Sylte I
    Chem Biol Drug Des; 2008 Jul; 72(1):50-7. PubMed ID: 18554251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural basis for differential activities of enantiomeric PPARγ agonists: Binding of S35 to the alternate site.
    Jang JY; Koh M; Bae H; An DR; Im HN; Kim HS; Yoon JY; Yoon HJ; Han BW; Park SB; Suh SW
    Biochim Biophys Acta Proteins Proteom; 2017 Jun; 1865(6):674-681. PubMed ID: 28342850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular switch in the glucocorticoid receptor: active and passive antagonist conformations.
    Schoch GA; D'Arcy B; Stihle M; Burger D; Bär D; Benz J; Thoma R; Ruf A
    J Mol Biol; 2010 Jan; 395(3):568-77. PubMed ID: 19913032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design.
    Montanari R; Saccoccia F; Scotti E; Crestani M; Godio C; Gilardi F; Loiodice F; Fracchiolla G; Laghezza A; Tortorella P; Lavecchia A; Novellino E; Mazza F; Aschi M; Pochetti G
    J Med Chem; 2008 Dec; 51(24):7768-76. PubMed ID: 19053776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Partial agonists activate PPARgamma using a helix 12 independent mechanism.
    Bruning JB; Chalmers MJ; Prasad S; Busby SA; Kamenecka TM; He Y; Nettles KW; Griffin PR
    Structure; 2007 Oct; 15(10):1258-71. PubMed ID: 17937915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamic correlation networks in human peroxisome proliferator-activated receptor-γ nuclear receptor protein.
    Fidelak J; Ferrer S; Oberlin M; Moras D; Dejaegere A; Stote RH
    Eur Biophys J; 2010 Oct; 39(11):1503-12. PubMed ID: 20496064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.
    Liu W; Lau F; Liu K; Wood HB; Zhou G; Chen Y; Li Y; Akiyama TE; Castriota G; Einstein M; Wang C; McCann ME; Doebber TW; Wu M; Chang CH; McNamara L; McKeever B; Mosley RT; Berger JP; Meinke PT
    J Med Chem; 2011 Dec; 54(24):8541-54. PubMed ID: 22070604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of covalent bond formation between PPARγ and oxo-fatty acids.
    Egawa D; Itoh T; Yamamoto K
    Bioconjug Chem; 2015 Apr; 26(4):690-8. PubMed ID: 25785518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.